- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 356 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 06.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | TransCode Therapeutics appoints Jack E. Stover to board of directors | 2 | Investing.com | ||
| 22.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 222 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen | |
| 11.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11.25 | TransCode Therapeutics appoints Michel Janicot as development officer | 1 | Investing.com | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.10.25 | Transcode Therapeutics ändert Bedingungen für Vorzugsaktien nach Aktionärszustimmung | 3 | Investing.com Deutsch | ||
| 27.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 249 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10.25 | TransCode Therapeutics Stock Jumps 21% On Polynoma Acquisition | 2 | RTTNews | ||
| 08.10.25 | TransCode Therapeutics stock soars after Polynoma acquisition | 3 | Investing.com | ||
| 08.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 244 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen | |
| 03.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 325 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 408 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| 02.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 249 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,60 | +0,39 % | BioNTech-Konkurrent Moderna: Rückschlag - Aktie rauscht erneut nach unten | Wie jüngst bekannt wurde, weigert sich die US-Arzneimittelbehörde FDA, den Zulassungsantrag für den experimentellen Grippeimpfstoff mRNA-1010 überhaupt zu prüfen. Die Aktie von Moderna geriet am Dienstag... ► Artikel lesen | |
| QIAGEN | 41,130 | -0,53 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| NOVAVAX | 7,281 | -0,41 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 16,960 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Advancing differentiated MC4R-based obesity programs into clinical development
Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with... ► Artikel lesen | |
| BRAIN BIOTECH | 2,210 | -2,21 % | Brain Biotech: Kursziel der Aktie wird gestutzt | Die Analysten der Deutschen Bank bezeichnen die jüngsten Zahlen von Brain Biotech als Enttäuschung. 2024/2025 sinkt der Umsatz von 54,6 Millionen Euro auf 49,6 Millionen Euro. Für das neue Geschäftsjahr... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - 10-Q, Quarterly Report | ||
| INOVIO PHARMACEUTICALS | 1,360 | -1,45 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,510 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| XOMA ROYALTY | 20,400 | -0,97 % | Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,470 | 0,00 % | What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? | ||
| ORAGENICS | 0,630 | 0,00 % | Oragenics, Inc.: Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy | Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia... ► Artikel lesen | |
| TENAX THERAPEUTICS | 10,300 | -5,50 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.02.2026 | The following instruments on XETRA do have their first trading 10.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.02.2026
Aktien
1 CNE100006V73 Auntea Jenny (Shanghai)... ► Artikel lesen | |
| BIOLINERX | 2,180 | -1,58 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| SERES THERAPEUTICS | 6,850 | +0,15 % | XFRA 1S90: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSERES THERA.NEW... ► Artikel lesen |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 8,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.